RT Journal Article
SR Electronic
T1 Factors associated with physician assessment of severity of asthma or COPD in NOVELTY
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2201
DO 10.1183/13993003.congress-2020.2201
VO 56
IS suppl 64
A1 Alberto Papi
A1 Helen K Reddel
A1 Alvar Agustí
A1 Gary P Anderson
A1 Aruna T Bansal
A1 Richard Beasley
A1 Elisabeth H Bel
A1 Christer Janson
A1 Barry Make
A1 Ian D Pavord
A1 David Price
A1 Eleni Rapsomaniki
A1 Donna K Finch
A1 Marianna Alacqua
A1 Hana Müllerová
A1 Rod Hughes
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/2201.abstract
AB Background: Determinates of how physicians assign severity in asthma or COPD are poorly understood. The NOVEL observational longiTudinal studY NOVELTY (NCT02760329) is a global, prospective, 3-year observational study of patients with a physician-assigned diagnosis or suspected diagnosis of asthma, asthma+COPD or COPD.Objective: To identify factors associated with physician-assigned severity of either asthma or COPD in the NOVELTY population.Methods: Ordinal regression analysis was used to identify factors associated with higher physician-assigned severity (severe vs mild or moderate; moderate vs mild) at baseline in patients with asthma (n=4,361) or COPD (n=2,931).Results: Factors associated with higher levels of physician-assigned severity are shown in the figure. Clinical features including exacerbation history in the past year, lower post-bronchodilator FEV1 % predicted, or FEV1/FVC ratio, reversibility and higher mMRC dyspnoea score were associated with greater severity for both diagnoses. Presence of allergic or non-allergic rhinitis or nasal polyps were notable factors in asthma, as was emphysema in COPD.Conclusions: Greater physician-assigned severity was associated with worse respiratory symptoms, lower lung function and exacerbation history in patients with asthma or COPD in NOVELTY; associations between greater severity and some diagnosis-related features and comorbidities varied between asthma and COPD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2201.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).